<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03986593</url>
  </required_header>
  <id_info>
    <org_study_id>990/2016</org_study_id>
    <nct_id>NCT03986593</nct_id>
  </id_info>
  <brief_title>Cryoablation of Bone Metastases From Endocrine Tumors</brief_title>
  <official_title>Cone-beam Computed Tomography Guided Percutaneous Cryoablation of Bone Metastases From Endocrine Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto do Cancer do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Sao Paulo General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto do Cancer do Estado de São Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the clinical response and safety of cone beam computed-tomography
      guided percutaneous cryoablation in bone metastases from thyroid, adrenal and neuroendocrine
      tumors in 30 patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thyroid neoplasms, as well as adrenal and neuroendocrine tumors have the potential to
      metastasize to bone. About 3% of patients with well-differentiated thyroid carcinomas develop
      secondary bone lesions, while adrenal and neuroendocrine tumors have 10% and 13% bone
      metastases rates, respectively. Spinal metastases are associated to a worst prognosis. The
      progressive systemic disease, the post-operative complications, and the pre-operative
      neurologic impairment were associated to a worst global survival rate in the thyroid cancer.
      Additionally, extensive spinal instrumentation of metastatic thyroid carcinoma was associated
      to greater complication rates. Interventional radiology offers promising techniques for the
      minimally invasive approach of bone metastases. Image-guided percutaneous radiofrequency
      ablation and cryoablation techniques have been studied in clinical trials and are considered
      effective options in pain palliation of patients with bone metastatic disease. These
      techniques may be associated with conventional treatment, as well as radiation therapy and
      percutaneous embolization, avoiding major surgical interventions and its complications.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 6, 2019</start_date>
  <completion_date type="Anticipated">June 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>open, single-arm group, prospective</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in the local disease status of the cryoablation treated bone metastases</measure>
    <time_frame>baseline (preprocedure); 01 week, 01 month, 03 months, 06 months, 12 months, 18 months, 24 months</time_frame>
    <description>absence of neurological impairment and/or pain evaluated by clinical examination and brief pain inventory forms avoiding additional radiation therapy or surgery need</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>evaluation of pain control</measure>
    <time_frame>baseline (preprocedure); 01 week, 01 month, 03 months, 06 months, 12 months, 18 months, 24 months</time_frame>
    <description>evaluation of pain control with the help of Brief Pain Inventory forms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evaluation of quality of life</measure>
    <time_frame>baseline (preprocedure), 01 week, 01 month, 03 months, 06 months, 12 months, 18 months, 24 months</time_frame>
    <description>evaluation of quality of life with the help of Brief Pain Inventory forms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants with treatment-related adverse events according to CTCAE 5.0</measure>
    <time_frame>baseline (preprocedure); 01 week, 01 month, 03 months, 06 months, 12 months, 18 months, 24 months</time_frame>
    <description>Major complications rates below 10%; Minor complication rates below 15%; Side effects rates bellow 20%; according to general guidelines (Society of Interventional Radiology - SIR);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>imaging evaluation (CT or MRI)</measure>
    <time_frame>baseline (preprocedure); 03 months, 06 months, 12 months, 24 months</time_frame>
    <description>Computed tomography or Magnetic resonance imaging evaluation of eligible treated lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>functional imaging evaluation (PET-CT)</measure>
    <time_frame>baseline (preprocedure); immediate post-procedure; 06 months</time_frame>
    <description>Computed tomography or Magnetic resonance imaging evaluation of eligible treated lesions</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Neoplasm Metastasis</condition>
  <condition>Thyroid Neoplasm</condition>
  <condition>Pheochromocytoma</condition>
  <condition>Adrenal Neoplasm</condition>
  <condition>Neuroendocrine Tumors</condition>
  <condition>Bone Metastases</condition>
  <arm_group>
    <arm_group_label>Cryoablation +- cementoplasty treated patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>cone beam computed tomography guided cryoablation +- cementoplasty</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>cryoablation</intervention_name>
    <description>cryoablation of bone metastases by cone beam-CT image-guidance</description>
    <arm_group_label>Cryoablation +- cementoplasty treated patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with bone metastases from thyroid, adrenal or neuroendocrine tumor diagnosis,
             associated to one of the following: pain; risk fracture; risk of compression of spinal
             cord; hypercalcemia; performance status (ECOG) 0-3; mean life expectancy over one
             month;

        Exclusion Criteria:

          -  age &lt; 18 years

          -  active anticoagulant therapy or uncorrectable coagulopathy

          -  pregnancy or breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ricardo MC Freitas, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto do Cancer do Estado de São Paulo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ricardo MC Freitas, PhD</last_name>
    <phone>551138932945</phone>
    <email>ricardo.freitas@hc.fm.usp.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ana O Hoff, PhD</last_name>
    <phone>551138932945</phone>
    <email>ana.hoff@hc.fm.usp.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto do Cancer do Estado de São Paulo</name>
      <address>
        <city>São Paulo</city>
        <zip>01246000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Talita R Vincunas</last_name>
      <phone>551138932945</phone>
      <email>talita.vincunas@hc.fm.usp.br</email>
    </contact>
    <contact_backup>
      <last_name>Ricardo MC Freitas, PhD</last_name>
      <phone>551138932945</phone>
      <email>ricardo.freitas@hc.fm.usp.br</email>
    </contact_backup>
    <investigator>
      <last_name>Ricardo MC Freitas, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ana O Hoff, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Candida VB Fragoso, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose Guilherme MP Caldas, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carlos A Buchpiguel, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Angela M Sousa, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>de Freitas RM, de Menezes MR, Cerri GG, Gangi A. Sclerotic vertebral metastases: pain palliation using percutaneous image-guided cryoablation. Cardiovasc Intervent Radiol. 2011 Feb;34 Suppl 2:S294-9. doi: 10.1007/s00270-010-0085-7. Epub 2010 Dec 18.</citation>
    <PMID>21170528</PMID>
  </reference>
  <reference>
    <citation>Callstrom MR, Charboneau JW, Goetz MP, Rubin J, Wong GY, Sloan JA, Novotny PJ, Lewis BD, Welch TJ, Farrell MA, Maus TP, Lee RA, Reading CC, Petersen IA, Pickett DD. Painful metastases involving bone: feasibility of percutaneous CT- and US-guided radio-frequency ablation. Radiology. 2002 Jul;224(1):87-97.</citation>
    <PMID>12091666</PMID>
  </reference>
  <reference>
    <citation>Munk PL, Murphy KJ, Gangi A, Liu DM. Fire and ice: percutaneous ablative therapies and cement injection in management of metastatic disease of the spine. Semin Musculoskelet Radiol. 2011 Apr;15(2):125-34. doi: 10.1055/s-0031-1275595. Epub 2011 Apr 15. Review.</citation>
    <PMID>21500132</PMID>
  </reference>
  <reference>
    <citation>Ferrer-Mileo L, Luque Blanco AI, González-Barboteo J. Efficacy of Cryoablation to Control Cancer Pain: A Systematic Review. Pain Pract. 2018 Nov;18(8):1083-1098. doi: 10.1111/papr.12707. Epub 2018 Jun 7.</citation>
    <PMID>29734509</PMID>
  </reference>
  <reference>
    <citation>Callstrom MR, Dupuy DE, Solomon SB, Beres RA, Littrup PJ, Davis KW, Paz-Fumagalli R, Hoffman C, Atwell TD, Charboneau JW, Schmit GD, Goetz MP, Rubin J, Brown KJ, Novotny PJ, Sloan JA. Percutaneous image-guided cryoablation of painful metastases involving bone: multicenter trial. Cancer. 2013 Mar 1;119(5):1033-41. doi: 10.1002/cncr.27793. Epub 2012 Oct 12.</citation>
    <PMID>23065947</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>May 22, 2019</study_first_submitted>
  <study_first_submitted_qc>June 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2019</study_first_posted>
  <last_update_submitted>August 6, 2019</last_update_submitted>
  <last_update_submitted_qc>August 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Bone Neoplasms</mesh_term>
    <mesh_term>Pheochromocytoma</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Endocrine Gland Neoplasms</mesh_term>
    <mesh_term>Adrenal Gland Neoplasms</mesh_term>
    <mesh_term>Bone Marrow Diseases</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data for all primary and secondary outcome measures will be made available.
Supporting information: Study protocol; Statistical Analysis Plan (SAP); Informed Consent Form (ICF); Clinical Study Report (CSR); Analytic Code; Time frame: Data will be available within 18 months of study completion. Access Criteria: Data access requests will be reviewed by an external Independent Review Panel. Requestors will be required to sign a Data Access Agreement.</ipd_description>
    <ipd_time_frame>Data will become available within 18 months of study completion and for 6 months.</ipd_time_frame>
    <ipd_access_criteria>Data access requests will be reviewed by an external Independent Review Panel. Requestors will be required to sign a Data Access Agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

